Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Todd Neale

September 09, 2016

News Conference News ESC 2016

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Michael O'Riordan

August 31, 2016

Presentation ESC 2016

“Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX

Presenter: Deepak L. Bhatt

August 31, 2016

News Conference News ESC 2016

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

Todd Neale

August 30, 2016

Presentation ESC 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presenter: Zuzana Motovska

August 30, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

Presentation ESC 2016

NIPPON Randomized Study: 6 Months vs 18 Months Dual Antiplatelet Treatment For Patients Underwent Bioabsorbable Polymer And Abluminal Coated DES Deployment

Presenter: Masato Nakamura

August 28, 2016

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

Presentation ESC 2015

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Presenter: Marco Valgimigli

September 01, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Advertisement

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

“Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

NIPPON Randomized Study: 6 Months vs 18 Months Dual Antiplatelet Treatment For Patients Underwent Bioabsorbable Polymer And Abluminal Coated DES Deployment

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

NSAIDs Plus Anticoagulants a Bad Combination

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content